FAMPRIDINE MR APOTEX fampridine 10mg modified release tablets blister pack

Pajjiż: Awstralja

Lingwa: Ingliż

Sors: Department of Health (Therapeutic Goods Administration)

Ingredjent attiv:

fampridine, Quantity: 10 mg

Disponibbli minn:

Arrotex Pharmaceuticals Pty Ltd

INN (Isem Internazzjonali):

Fampridine

Għamla farmaċewtika:

Tablet, modified release

Kompożizzjoni:

Excipient Ingredients: magnesium stearate; colloidal anhydrous silica; macrogol 8000; polyvinyl alcohol; titanium dioxide; hypromellose; purified talc; microcrystalline cellulose

Rotta amministrattiva:

Oral

Unitajiet fil-pakkett:

56 tablets

Tip ta 'preskrizzjoni:

(S4) Prescription Only Medicine

Indikazzjonijiet terapewtiċi:

FAMPRIDINE MR APOTEX modified release tablets are indicated for the symptomatic improvement of walking ability in adult patients with Multiple Sclerosis who have shown improvement after 8 weeks of treatment.

Sommarju tal-prodott:

Visual Identification: White coloured, oval-shaped, biconvex film-coated tablets engraved "APO" on one side and "DAL 10" on the other side.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

L-istatus ta 'awtorizzazzjoni:

Licence status A

Data ta 'l-awtorizzazzjoni:

2017-08-25